{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:15:18Z","timestamp":1789215318582,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,6,8]],"date-time":"2007-06-08T00:00:00Z","timestamp":1181260800000},"content-version":"vor","delay-in-days":1438,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Congestive Heart Failure"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:p>Hyperkalemia is a common occurrence in patients with congestive heart failure, particularly when renal failure coexists. The level of renal function in congestive heart failure is often difficult to ascertain because good measurement tools for estimation of renal function are not available. Serum creatinine values have often been offered as a good gauge of renal function, although in most cases true renal function is appreciably lower than the estimate derived from a specific serum creatinine value. Thus, patients with congestive heart failure very commonly, particularly in the advanced stages of the disease, have moderate renal insufficiency, either due to specific heart failure\u2010related renal perfusion changes or as the result of renal involvement from the same processes having caused the heart failure, as is the case with diabetes. It is in this setting of mild\u2010to\u2010moderate levels of renal failure that therapies, such as angiotensin\u2010converting inhibitors, angiotensin\u2010receptor blockers, and aldosterone\u2010receptor antagonists, are administered either individually or collectively. Each of these drug classes reduces the homeostatic ability to eliminate ingested potassium loads by the renal route and increase the tendency to evolve into a hyperkalemic state. This is noteworthy because aldosterone\u2010receptor antagonists are increasingly considered as important therapies in the long\u2010term management of heart failure. Spironolactone has been employed in this capacity and a new aldosterone\u2010receptor antagonist, eplerenone, will become available in the near future, which further increases the importance of evaluating and treating the hyperkalemia risk in a timely manner.<\/jats:p>","DOI":"10.1111\/j.1527-5299.2003.02397.x","type":"journal-article","created":{"date-parts":[[2007,6,8]],"date-time":"2007-06-08T10:04:18Z","timestamp":1181297058000},"page":"224-229","source":"Crossref","is-referenced-by-count":26,"title":["Hyperkalemia, Congestive Heart Failure, and Aldosterone Receptor Antagonism"],"prefix":"10.1111","volume":"9","author":[{"given":"Domemic A.","family":"Sica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.B.","family":"Gehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde","family":"Yancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(89)90866-1"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199207020-00007"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90921-5"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1980.14"},{"key":"e_1_2_5_6_2","volume-title":"Clinical Disorders of Fluid and Electrolyte Metabolism","author":"Kleeman K","year":"1980"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.137.7.842"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2337\/diab.32.11.1028","article-title":"Impairment of insulin\u2010mediated glucose metabolism by hyperosmolarity in man","volume":"32","author":"Bratusch\u2010Marrain PR","year":"1983","journal-title":"Diabetes"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198002213020803"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80080-1"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6372.1189"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.189"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02581-X"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061372"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.1.26"},{"key":"e_1_2_5_16_2","first-page":"67","article-title":"Renal failure related to angiotensin\u2010converting enzyme inhibitors","volume":"17","author":"Textor SC","year":"1997","journal-title":"Semin Nephrol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90415-6"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(96)90365-8"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2000.00381.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02580-8"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02694-3"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.11.1605"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199803000-00013"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90934-4"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(60)90320-9"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.145.6.1070"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.V281279","article-title":"Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine","volume":"2","author":"Kamel KS","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000022089"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.43869000.x"},{"key":"e_1_2_5_33_2","first-page":"544","article-title":"The influence of hypocalcemia induced by sodium ethylenediamine acetate on the toxicity of potassium: an experimental study","volume":"46","author":"Braun HA","year":"1955","journal-title":"J Lab Clin Med"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(62)90033-9"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-0736(99)90020-1"},{"key":"e_1_2_5_36_2","first-page":"736","article-title":"Clinical disorders of hyperkalemia","author":"DeFronzo RA","year":"1994","journal-title":"Maxwell and Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199200101-00004"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4101.096153"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022050-00003"},{"key":"e_1_2_5_40_2","first-page":"315","article-title":"Elderly heart failure patients with drug\u2010induced serious hyperkalemia","volume":"12","author":"Vanpee D","year":"2000","journal-title":"Aging"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00642-8"}],"container-title":["Congestive Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-5299.2003.02397.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-5299.2003.02397.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T04:47:40Z","timestamp":1697172460000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-5299.2003.02397.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1111\/j.1527-5299.2003.02397.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-5299.2003.02397.x","archive":["Portico"],"relation":{},"ISSN":["1527-5299","1751-7133"],"issn-type":[{"value":"1527-5299","type":"print"},{"value":"1751-7133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}